Why a Texas Physician Is Selling Ivermectin for Hantavirus

By VirentaNews Staff — May 09, 2026

In a striking convergence of public health concern and controversial medicine, two Texans who returned from a Caribbean cruise are now battling hantavirus, a rare but often fatal respiratory disease with no approved antiviral treatment. Amid the scare, Dr. Mary Bowden, a Houston physician known for her vocal advocacy of ivermectin during the COVID-19 pandemic, has begun selling the antiparasitic drug directly to patients as a preventive measure against hantavirus—despite zero clinical evidence supporting its efficacy and stern warnings from infectious disease experts. The case has ignited a firestorm in Texas’s medical community, particularly as a recently enacted state law now permits pharmacists to dispense ivermectin without a prescription, a move critics say undermines scientific medicine and opens the door to potentially dangerous self-treatment.

The Rise of a Controversial Medical Figure

Dr. Mary Bowden has emerged as a polarizing figure in Texas’s medical landscape, gaining national attention during the pandemic for promoting ivermectin as a frontline treatment for COVID-19—a stance sharply at odds with the FDA, CDC, and World Health Organization. Despite widespread debunking of ivermectin’s efficacy against viral infections, Bowden continued to advocate for its use, appearing in media interviews and online forums to endorse off-label prescriptions. Now, she has pivoted her messaging to hantavirus, a zoonotic disease transmitted through rodent urine, droppings, or saliva, typically contracted in rural or wilderness areas. While hantavirus pulmonary syndrome (HPS) has a mortality rate of around 38%, according to the U.S. Centers for Disease Control and Prevention, no antiviral therapy has been proven effective, and treatment remains supportive. Bowden’s pivot raises alarm among public health officials who fear misinformation could lead patients to rely on unproven therapies while delaying life-saving care.

A New Law Fuels Medical Tensions

The controversy deepens against the backdrop of Texas Senate Bill 1106, which took effect in September 2023 and allows pharmacists to dispense ivermectin without a physician’s prescription under certain conditions. The law, backed by libertarian and anti-establishment lawmakers, was framed as enhancing patient access to medications, but it has been fiercely opposed by the Texas Medical Association (TMA), which called it a threat to patient safety and medical integrity. The TMA warns that bypassing physician oversight increases the risk of misuse, adverse effects, and false confidence in unvalidated treatments. In Bowden’s case, the law enables her to legally distribute ivermectin through affiliated compounding pharmacies, even as she markets it for off-label and scientifically unsupported uses. Critics argue that such policies create a dangerous precedent, allowing individual practitioners to circumvent established medical consensus.

Scientific Consensus vs. Medical Maverickry

There is no peer-reviewed evidence that ivermectin has any effect on hantavirus. The drug, originally developed to treat parasitic infections like river blindness and strongyloidiasis, works by paralyzing invertebrate nervous systems—not by inhibiting viruses. Hantaviruses, part of the Bunyaviridae family, replicate inside human cells and trigger a severe immune overreaction leading to pulmonary edema and respiratory failure. Antiviral studies on hantavirus have explored ribavirin and monoclonal antibodies, but none have yielded definitive results. Experts stress that prevention—avoiding rodent-infested areas, sealing homes, and using protective gear during cleanup—is the only proven strategy. Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases, previously stated that promoting ivermectin for viral diseases ‘is not only wrong, it’s dangerous.’ The World Health Organization similarly advises against its use outside clinical trials for any viral illness, emphasizing that inappropriate use can lead to toxicity, drug resistance, and public health erosion.

Implications for Public Health and Trust

The promotion of ivermectin for hantavirus risks undermining public trust in science-based medicine, particularly in regions already skeptical of mainstream health guidance. Patients who believe they are protected by ivermectin may ignore early symptoms—fever, fatigue, muscle aches, and shortness of breath—delaying emergency care when time is critical. HPS progresses rapidly, and survival often depends on early intensive care support. Moreover, widespread off-label use of ivermectin, especially in high doses, carries risks of dizziness, nausea, seizures, and liver damage. Public health advocates warn that when physicians market unproven treatments, they blur the line between medical practice and commercial enterprise, potentially exploiting fear during health scares. The case also highlights a growing divide between state legislation and medical expertise, where political decisions increasingly override clinical guidelines.

Expert Perspectives

Infectious disease specialists largely condemn Bowden’s actions. Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, called the promotion of ivermectin for viral diseases ‘a disservice to public health.’ Others argue that while patient autonomy is important, it must be balanced with physician responsibility to avoid harm. Conversely, some libertarian-leaning physicians argue that patients should have access to all possible treatments, especially when no alternatives exist. However, even within this camp, few defend using a drug with no mechanistic plausibility against a deadly virus. The American Society of Tropical Medicine and Hygiene has reiterated that ‘hope is not a strategy’ when facing emerging infectious diseases.

As hantavirus cases remain rare but deadly, and with no antiviral cure on the horizon, the medical community faces a dual challenge: advancing research while combating misinformation. The case of Dr. Bowden and the Texas ivermectin law may set a precedent for how states balance patient access, medical authority, and scientific integrity. With another cruise-linked case under investigation, health officials urge caution, clarity, and reliance on evidence—not anecdote.

Source: Reddit